A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial.

[1]  T. Casale,et al.  Validation of Patient-Reported Outcomes for Clinical Trials in Allergic Rhinitis: A Systematic Review. , 2019, The journal of allergy and clinical immunology. In practice.

[2]  Y. Okamoto,et al.  Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[3]  S. Durham,et al.  Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis , 2018, Current Treatment Options in Allergy.

[4]  O. Pfaar,et al.  Placebo effects in allergen immunotherapy: an experts’ opinion , 2018, Allergo Journal International.

[5]  M. Xian,et al.  Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy , 2018, The Journal of Immunology.

[6]  M. Blaiss,et al.  The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  A. Sheikh,et al.  Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products , 2018, Allergy.

[8]  D. Léger,et al.  Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children , 2017, Allergy, Asthma & Clinical Immunology.

[9]  P. Demoly,et al.  Allergic rhinitis increases the risk of driving accidents. , 2017, The Journal of allergy and clinical immunology.

[10]  T. Casale,et al.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles , 2017, Current Allergy and Asthma Reports.

[11]  Manoj Kumar Singh,et al.  House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis , 2016, Allergy.

[12]  T. Casale,et al.  Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. , 2017, The journal of allergy and clinical immunology. In practice.

[13]  L. Cox,et al.  Is the Benefit From Prescribing Epinephrine Autoinjectors for Sublingual Immunotherapy Worth the Cost? Lessons Learned From Clinical Trials. , 2017, The journal of allergy and clinical immunology. In practice.

[14]  D. Bernstein,et al.  Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. , 2016, The Journal of allergy and clinical immunology.

[15]  S. Durham,et al.  Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. , 2016, The Journal of allergy and clinical immunology.

[16]  William H. Yang,et al.  300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis , 2016, Expert review of clinical immunology.

[17]  A. Linneberg,et al.  Burden of allergic respiratory disease: a systematic review , 2016, Clinical and Molecular Allergy.

[18]  William H. Yang,et al.  Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. , 2016, The Journal of allergy and clinical immunology.

[19]  P. Demoly,et al.  “A year-long, fortnightly, observational survey in three European countries of patients with respiratory allergies induced by house dust mites: Methodology, demographics and clinical characteristics” , 2016, BMC Pulmonary Medicine.

[20]  J. Virchow,et al.  Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. , 2016, JAMA.

[21]  F. Chew,et al.  Patterns of IgE sensitization in house dust mite‐allergic patients: implications for allergen immunotherapy , 2016, Allergy.

[22]  R. Van Ree,et al.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.

[23]  V. Backer,et al.  Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. , 2016, The Journal of allergy and clinical immunology.

[24]  B. Samoliński,et al.  Sublingual immunotherapy (SLIT)--indications, mechanism, and efficacy: Position paper prepared by the Section of Immunotherapy, Polish Society of Allergy. , 2015, Annals of agricultural and environmental medicine : AAEM.

[25]  J. Virchow,et al.  House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies. , 2015, The journal of allergy and clinical immunology. In practice.

[26]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[27]  P. Demoly,et al.  Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.

[28]  E. Vuurman,et al.  Allergic rhinitis is a risk factor for traffic safety. , 2014, Allergy.

[29]  P. Demoly,et al.  Rhinitis , sinusitis , and upper airway disease Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis , 2016 .

[30]  P. Demoly,et al.  A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis , 2014, BMC Medicine.

[31]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[32]  H. Malling,et al.  Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study , 2014, Clinical and Translational Allergy.

[33]  T. Casale,et al.  An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. , 2013, The Journal of allergy and clinical immunology.

[34]  C. Akdis,et al.  IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. , 2013, The Journal of allergy and clinical immunology.

[35]  R. Naclerio,et al.  Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. , 2012, Allergy and asthma proceedings.

[36]  P. Demoly,et al.  Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile , 2012, Allergy.

[37]  M. Songu,et al.  The burden of allergic rhinitis and asthma , 2012, Therapeutic advances in respiratory disease.

[38]  H. Malling,et al.  Rhinitis , sinusitis , and upper airway disease Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen – induced rhinoconjunctivitis , 2011 .

[39]  H. Neffen,et al.  Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  D. Bernstein,et al.  Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. , 2011, The Journal of allergy and clinical immunology.

[41]  W. Thomas.  Geography of house dust mite allergens. , 2010, Asian Pacific journal of allergy and immunology.

[42]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[43]  W. Thomas,et al.  House dust mite allergens in asthma and allergy. , 2010, Trends in molecular medicine.

[44]  S. Durham,et al.  Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. , 2010, The Journal of allergy and clinical immunology.

[45]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[46]  S. Durham,et al.  Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. , 2008, The Journal of allergy and clinical immunology.

[47]  T. Fujimura,et al.  Relationships Among Nasal Obstruction, Daytime Sleepiness, and Quality of Life , 2006, The Laryngoscope.

[48]  Deborah Jarvis,et al.  Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II. , 2006, The Journal of allergy and clinical immunology.

[49]  J. Bousquet,et al.  Allergic rhinitis and its impact on asthma. , 2001, The Journal of allergy and clinical immunology.

[50]  G. Scadding,et al.  Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. , 2000, Clinical otolaryngology and allied sciences.

[51]  E. Juniper,et al.  Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. , 1999, The Journal of allergy and clinical immunology.

[52]  P. Norman,et al.  Immunotherapy with allergens. , 1987, JAMA.

[53]  M. Mardiney,et al.  Dose response of IgE and IgG antibodies during ragweed immunotherapy. , 1984, The Journal of allergy and clinical immunology.

[54]  L. Lichtenstein,et al.  A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. , 1971, Annals of internal medicine.